The Germany Asthma and COPD Therapeutics Market was valued at US $1.222 Bn in 2022, and is predicted to grow at (CAGR) of 3.40% from 2023 to 2030, to US $1.597 Bn by 2030. The key drivers of this industry include the rise in the prevalence of COPD and asthma, a focus on quality of life, supportive regulations, and others. The industry is primarily dominated by players such as, GlaxoSmithKline, Teva, Pfizer, Novartis, Sulfateq, AstraZeneca, and Boehringer Ingelheim, among others.
The Germany Asthma and COPD Therapeutics Market is at around US $1.22 Bn in 2022 and is projected to reach US $1.6 Bn in 2030, exhibiting a CAGR of 3.40% during the forecast period.
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are chronic respiratory disorders that damage the airways and cause difficulty in breathing. Asthma is characterized by inflammation and constriction of the airways, which are frequently induced by allergens, irritants, or exercise. Common symptoms include wheezing, shortness of breath, tightness in the chest, and coughing, which are associated with risk factors such as a family history of respiratory infections. COPD includes chronic bronchitis and emphysema, which cause congested airways, and smoking has been identified as a key risk factor. Identifiable COPD symptoms include a persistent cough, increased mucus production, and exhaustion. Bronchodilators are used to relieve airway tightness in Asthma, and anti-inflammatory medicines are used to treat inflammation in COPD. Medications from firms like GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim are widely recommended.
COPD affects about 12% of the population, and the prevalence of asthma ranges from approximately 7% to 12% among both adults and children in France. These statistics are closely linked to increased levels of smoking, air pollution, and other environmental factors in the population. The primary factors driving the market are the surge in the prevalence of Asthma and COPD, technological advancements, a favorable regulatory landscape, and others. However, the high costs of advanced treatment, underdiagnosis, and increasing generic medications are a few factors that limit the market's potential.
Market Growth Drivers
Rising disease prevalence: The estimated prevalence of COPD in Germany is around 12% for the population over 40 years of age which translates to roughly 7 million individuals. Subsequently, the prevalence of asthma is approximately 7% in adults and 12% in children, with more than 1 million children currently suffering from asthma in Germany. With the aging of Germany's population, it is anticipated that the occurrence of both COPD and asthma will rise, attributed to age-related alterations in lung function and heightened vulnerability to respiratory conditions. This translates into a huge patient pool that requires regular treatment, leading to market growth.
Focus on quality of life: While current treatments effectively manage symptoms, there is a continuous need for novel medications that handle disease progression, prevent poor prognosis, and provide long-term management. Patients seek solutions that reduce limitations and improve their overall well-being, fueling the demand for convenient and effective treatment options.
Technological advancements: Exploration into new drug targets, formulations, and delivery systems such as inhalers and nebulizers offers the potential for more efficient and patient-friendly treatment alternatives. The integration of AI applications in diagnostics, treatment selection, and drug development has the capacity to expedite innovation and customize healthcare delivery in Germany.
Supportive regulatory landscape: Healthcare policies in Germany prioritize enhancing access to innovative treatments and early diagnosis, contributing to the positive impact on the market for Asthma and COPD therapeutics. Regulatory reforms are designed to streamline the approval process for new and effective medications, thereby promoting market growth.
Market Restraints
High Cost of Treatment:
Effective management of both COPD and asthma necessitates the long-term use of medications, which constitutes a significant financial burden. The elevated cost of treatment can present a barrier for patients, especially those with limited financial means. A recent estimate suggested the direct medical costs of COPD in Germany at approximately $8 billion, demonstrating the substantial financial strain on both patients and healthcare systems.
Underdiagnosis and misdiagnosis: Even with a significant occurrence of COPD in Germany, numerous cases go undetected or are misdiagnosed. Estimates indicate that only 20–25% of individuals with COPD receive a proper diagnosis. This delay in initiating appropriate treatment can mediate disease progression, contributing to increased long-term healthcare costs.
Rise of generic medications: The growing presence of generic and biosimilar drugs may exert downward pressure on the prices of branded medications, influencing the overall revenue of the market. While this is cost-effective for patients, it also has the potential to impact the profitability of pharmaceutical companies that invest in the research and development of new therapies.
July 2023, Lupin Pharmaceutical Company introduced a pressurized metered-dose inhaler called Luforbec in Germany. This inhaler combines a corticosteroid and a long-acting beta2-agonist and is designed for the treatment of both asthma and chronic obstructive pulmonary disease (COPD).
The regulatory landscape governing healthcare in Germany is influenced by directives, standards, and safety regulations issued both at the national level and by the European Union (EU). Oversight of medical devices is the responsibility of the Federal Institute for Drugs and Medical Devices (BfArM), which enforces the Medical Devices Act and the Medical Devices Regulation in alignment with EU directives. Germany's healthcare system is characterized by a decentralized decision-making structure involving the federal government, state laws, and regional associations of sickness funds. The Federal Joint Committee plays a pivotal role in determining the covered services of sickness funds, relying on evidence from comparative effectiveness reviews and health assessments.
Companies aiming for healthcare licensure in Germany must undergo a thorough registration process overseen by the BfArM, facilitated through the electronic portal DIMDI. For new entrants to the German market, a comprehensive understanding of the regulatory environment is essential to ensuring compliance with the relevant regulations.
Key Players
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Disease Type
By Medication Class
By Delivery Device
By Route of Administration
By End User
By Distribution Channel
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
Need more?